Loading…

Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates

Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale advances 2020-12, Vol.2 (12), p.5666-5681
Main Authors: Piersimoni, Maria Elena, Teng, Xiangyu, Cass, Anthony E. G, Ying, Liming
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403
cites cdi_FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403
container_end_page 5681
container_issue 12
container_start_page 5666
container_title Nanoscale advances
container_volume 2
creator Piersimoni, Maria Elena
Teng, Xiangyu
Cass, Anthony E. G
Ying, Liming
description Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system into SH-SY5Y cells, a cellular model commonly used to study Parkinson's disease. We tested the nanoconjugates of GNPs-LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs-α-Syn). GNPs-LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs-LA may serve as promising drug delivery vehicles conveying antioxidant molecules for the treatment of Parkinson's disease. Lipoic acid-gold nanoconjugates (GNPs-LA) decrease GNPs-α-synuclein-induced oxidative stress on living cells, making them a promising antioxidant system for the treatment of Parkinson's disease.
doi_str_mv 10.1039/d0na00688b
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9416995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716932689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403</originalsourceid><addsrcrecordid>eNpVkc9OHDEMxqMKVBBw6b0oR1RpIJnM30ulhbaAhOilPUeexDsEzSbbOIO6j9UX4ZkYdukCJ3-Sf_5s-WPskxSnUqj2zAoPQlRN031g-3kpq0zkSuy80XvsiOheCJHLoijq9iPbU5VUqinLfUYzn1z46yz4xAe3DM5wMM5OugdvM7rDYeB9GCz34IMJ_n7sISFx6MF5Snw9nNwDckoRibiBkdDybsUf_2W08qMZ0PmJ7yOuRw_Z7hwGwqOXesB-__j-6-Iqu_l5eX0xu8lMUciUNY1UCFB3UtY5lFh2nTJNZY3CGi1CCSCrWljRSZjbMu-sQityY7GaQ1EIdcC-bnyXY7dAa9CnCINeRreAuNIBnH7f8e5O9-FBt4Ws2racDE5eDGL4MyIlvXBkpoeAxzCSzuuJU3nVtBP6ZYOaGIgizrdrpNDPQelv4na2Dup8go_fHrZF_8cyAZ83QCSz7b4mrZ4A3K2dSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716932689</pqid></control><display><type>article</type><title>Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates</title><source>PubMed Central</source><creator>Piersimoni, Maria Elena ; Teng, Xiangyu ; Cass, Anthony E. G ; Ying, Liming</creator><creatorcontrib>Piersimoni, Maria Elena ; Teng, Xiangyu ; Cass, Anthony E. G ; Ying, Liming</creatorcontrib><description>Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system into SH-SY5Y cells, a cellular model commonly used to study Parkinson's disease. We tested the nanoconjugates of GNPs-LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs-α-Syn). GNPs-LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs-LA may serve as promising drug delivery vehicles conveying antioxidant molecules for the treatment of Parkinson's disease. Lipoic acid-gold nanoconjugates (GNPs-LA) decrease GNPs-α-synuclein-induced oxidative stress on living cells, making them a promising antioxidant system for the treatment of Parkinson's disease.</description><identifier>ISSN: 2516-0230</identifier><identifier>EISSN: 2516-0230</identifier><identifier>DOI: 10.1039/d0na00688b</identifier><identifier>PMID: 36133855</identifier><language>eng</language><publisher>England: RSC</publisher><subject>Chemistry</subject><ispartof>Nanoscale advances, 2020-12, Vol.2 (12), p.5666-5681</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>This journal is © The Royal Society of Chemistry 2020 RSC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403</citedby><cites>FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403</cites><orcidid>0000-0001-9752-6292 ; 0000-0001-8881-4786</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416995/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416995/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36133855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piersimoni, Maria Elena</creatorcontrib><creatorcontrib>Teng, Xiangyu</creatorcontrib><creatorcontrib>Cass, Anthony E. G</creatorcontrib><creatorcontrib>Ying, Liming</creatorcontrib><title>Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates</title><title>Nanoscale advances</title><addtitle>Nanoscale Adv</addtitle><description>Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system into SH-SY5Y cells, a cellular model commonly used to study Parkinson's disease. We tested the nanoconjugates of GNPs-LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs-α-Syn). GNPs-LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs-LA may serve as promising drug delivery vehicles conveying antioxidant molecules for the treatment of Parkinson's disease. Lipoic acid-gold nanoconjugates (GNPs-LA) decrease GNPs-α-synuclein-induced oxidative stress on living cells, making them a promising antioxidant system for the treatment of Parkinson's disease.</description><subject>Chemistry</subject><issn>2516-0230</issn><issn>2516-0230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkc9OHDEMxqMKVBBw6b0oR1RpIJnM30ulhbaAhOilPUeexDsEzSbbOIO6j9UX4ZkYdukCJ3-Sf_5s-WPskxSnUqj2zAoPQlRN031g-3kpq0zkSuy80XvsiOheCJHLoijq9iPbU5VUqinLfUYzn1z46yz4xAe3DM5wMM5OugdvM7rDYeB9GCz34IMJ_n7sISFx6MF5Snw9nNwDckoRibiBkdDybsUf_2W08qMZ0PmJ7yOuRw_Z7hwGwqOXesB-__j-6-Iqu_l5eX0xu8lMUciUNY1UCFB3UtY5lFh2nTJNZY3CGi1CCSCrWljRSZjbMu-sQityY7GaQ1EIdcC-bnyXY7dAa9CnCINeRreAuNIBnH7f8e5O9-FBt4Ws2racDE5eDGL4MyIlvXBkpoeAxzCSzuuJU3nVtBP6ZYOaGIgizrdrpNDPQelv4na2Dup8go_fHrZF_8cyAZ83QCSz7b4mrZ4A3K2dSw</recordid><startdate>20201215</startdate><enddate>20201215</enddate><creator>Piersimoni, Maria Elena</creator><creator>Teng, Xiangyu</creator><creator>Cass, Anthony E. G</creator><creator>Ying, Liming</creator><general>RSC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9752-6292</orcidid><orcidid>https://orcid.org/0000-0001-8881-4786</orcidid></search><sort><creationdate>20201215</creationdate><title>Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates</title><author>Piersimoni, Maria Elena ; Teng, Xiangyu ; Cass, Anthony E. G ; Ying, Liming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piersimoni, Maria Elena</creatorcontrib><creatorcontrib>Teng, Xiangyu</creatorcontrib><creatorcontrib>Cass, Anthony E. G</creatorcontrib><creatorcontrib>Ying, Liming</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nanoscale advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piersimoni, Maria Elena</au><au>Teng, Xiangyu</au><au>Cass, Anthony E. G</au><au>Ying, Liming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates</atitle><jtitle>Nanoscale advances</jtitle><addtitle>Nanoscale Adv</addtitle><date>2020-12-15</date><risdate>2020</risdate><volume>2</volume><issue>12</issue><spage>5666</spage><epage>5681</epage><pages>5666-5681</pages><issn>2516-0230</issn><eissn>2516-0230</eissn><abstract>Gold nanoparticles are becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson's disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system into SH-SY5Y cells, a cellular model commonly used to study Parkinson's disease. We tested the nanoconjugates of GNPs-LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs-α-Syn). GNPs-LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs-LA may serve as promising drug delivery vehicles conveying antioxidant molecules for the treatment of Parkinson's disease. Lipoic acid-gold nanoconjugates (GNPs-LA) decrease GNPs-α-synuclein-induced oxidative stress on living cells, making them a promising antioxidant system for the treatment of Parkinson's disease.</abstract><cop>England</cop><pub>RSC</pub><pmid>36133855</pmid><doi>10.1039/d0na00688b</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-9752-6292</orcidid><orcidid>https://orcid.org/0000-0001-8881-4786</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2516-0230
ispartof Nanoscale advances, 2020-12, Vol.2 (12), p.5666-5681
issn 2516-0230
2516-0230
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9416995
source PubMed Central
subjects Chemistry
title Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-synuclein aggregates
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A51%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antioxidant%20lipoic%20acid%20ligand-shell%20gold%20nanoconjugates%20against%20oxidative%20stress%20caused%20by%20%CE%B1-synuclein%20aggregates&rft.jtitle=Nanoscale%20advances&rft.au=Piersimoni,%20Maria%20Elena&rft.date=2020-12-15&rft.volume=2&rft.issue=12&rft.spage=5666&rft.epage=5681&rft.pages=5666-5681&rft.issn=2516-0230&rft.eissn=2516-0230&rft_id=info:doi/10.1039/d0na00688b&rft_dat=%3Cproquest_pubme%3E2716932689%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c441t-8813eaa7b1172a5e5bb3c86dc3e7edea5aa1670d0b1afd52bd3ed02cde6fa4403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2716932689&rft_id=info:pmid/36133855&rfr_iscdi=true